Jason N. Butler
Stock Analyst at Citizens
(3.65)
# 3,327
Out of 5,182 analysts
20
Total ratings
60%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Jason N. Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NERV Minerva Neurosciences | Initiates: Market Outperform | $14 | $6.24 | +124.36% | 1 | Apr 15, 2026 | |
| PGEN Precigen | Maintains: Market Outperform | $8 → $9 | $4.08 | +120.59% | 2 | Mar 26, 2026 | |
| NSRX Nasus Pharma | Maintains: Market Outperform | $19 → $18 | $3.20 | +462.50% | 1 | Mar 26, 2026 | |
| ESPR Esperion Therapeutics | Maintains: Market Outperform | $4 → $5 | $2.01 | +148.76% | 1 | Mar 13, 2026 | |
| GHRS GH Research | Maintains: Market Outperform | $39 → $42 | $19.87 | +111.35% | 1 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Market Outperform | $925 → $944 | $785.64 | +20.16% | 1 | Feb 27, 2026 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $8 → $10 | $4.06 | +146.31% | 1 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Market Outperform | $34 → $35 | $22.43 | +56.04% | 3 | Feb 26, 2026 | |
| ACHV Achieve Life Sciences | Initiates: Market Outperform | $19 | $4.20 | +352.38% | 1 | Nov 25, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Market Outperform | $77 → $80 | $35.23 | +127.08% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $22 | $20.96 | +4.96% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $17 | $3.34 | +408.98% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $95 → $114 | $113.58 | +0.37% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $22 | $7.69 | +186.09% | 1 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $63.00 | +23.81% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $19 → $18 | $10.07 | +78.84% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $78 | $64.61 | +20.72% | 1 | Aug 6, 2025 |
Minerva Neurosciences
Apr 15, 2026
Initiates: Market Outperform
Price Target: $14
Current: $6.24
Upside: +124.36%
Precigen
Mar 26, 2026
Maintains: Market Outperform
Price Target: $8 → $9
Current: $4.08
Upside: +120.59%
Nasus Pharma
Mar 26, 2026
Maintains: Market Outperform
Price Target: $19 → $18
Current: $3.20
Upside: +462.50%
Esperion Therapeutics
Mar 13, 2026
Maintains: Market Outperform
Price Target: $4 → $5
Current: $2.01
Upside: +148.76%
GH Research
Mar 6, 2026
Maintains: Market Outperform
Price Target: $39 → $42
Current: $19.87
Upside: +111.35%
argenx SE
Feb 27, 2026
Maintains: Market Outperform
Price Target: $925 → $944
Current: $785.64
Upside: +20.16%
Ironwood Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.06
Upside: +146.31%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $34 → $35
Current: $22.43
Upside: +56.04%
Achieve Life Sciences
Nov 25, 2025
Initiates: Market Outperform
Price Target: $19
Current: $4.20
Upside: +352.38%
Rapport Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $77 → $80
Current: $35.23
Upside: +127.08%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $18 → $22
Current: $20.96
Upside: +4.96%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $9 → $17
Current: $3.34
Upside: +408.98%
Sep 25, 2025
Maintains: Market Outperform
Price Target: $95 → $114
Current: $113.58
Upside: +0.37%
Sep 9, 2025
Reiterates: Market Outperform
Price Target: $22
Current: $7.69
Upside: +186.09%
Sep 2, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $63.00
Upside: +23.81%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $19 → $18
Current: $10.07
Upside: +78.84%
Aug 6, 2025
Maintains: Market Outperform
Price Target: $91 → $78
Current: $64.61
Upside: +20.72%